Easywell Biomedicals Inc.

What Easywell Biomedicals Inc. does

Easywell Biomedicals Inc. (TPEX: 1799.TWO) is a Taiwan-based biopharmaceutical company operating across three business sectors — pharmaceuticals, regenerative medicine, and medical devices — with primary operations in difficult-to-formulate generic drugs (P4 Paragraph IV ANDA) and 505(b)(2) new drug applications targeting high-barrier, limited-competition niches. The company was incorporated in 1998 as Actherm, Inc., pivoted into pharmaceuticals through the 2014 acquisition of Magnifica Inc., and expanded into regenerative medicine via the 2016 acquisition of Transwell Biotech. Subsidiaries include Tulex Pharmaceuticals Inc. (Cranbury, New Jersey, USA; cGMP drug R&D and manufacturing for solid and liquid dosage forms), Magnifica Inc. (USA; API trading and Rx-to-OTC switch products sold through Costco and Walmart), and Jiangsu HuaHan Pharma-Tech (Nanjing, China; GMP manufacturing and 33-province/region sales of HH-001 Sacubitril/Valsartan). The company is headquartered in Hsinchu Science Park, Taiwan.

Easywell's competitive position rests on two proprietary drug delivery platform technologies: a Bioavailability Enhancement Sizing Technology (a micro milling process for particle size reduction, positioned as more efficient and reproducible than conventional nano-sizing) and a Gradient Release Enabling Advanced Technology (proprietary film/matrix process enabling programmable release profiles), plus an oral liquid extended-release formulation capability. These are protected by 20+ issued patents and have supported a track record of 20+ ANDA approvals and 6+ NDA approvals, including First-to-File Paragraph IV generics (TLX-001, TLX-004, TLX-005, TLX-007, TLX-015, TLX-018) and 505(b)(2) new drugs (ET-101, TLX-041, TLX-042, TLX-047, TLX-050, TLX-054, ARD-501, TWB-201). The pipeline also includes regenerative products such as TWB-103 fetal skin cell wound dressing.

The business model is partnership-driven: Easywell/Tulex retains formulation R&D and cGMP manufacturing, while co-development partners (Eton Pharmaceuticals, Handa Neuroscience, Azurity Pharmaceuticals, Artisan Therapeutics, Taiwan Yok Chemical, plus confidential multinational pharma companies) fund clinical development, hold ex-Asia market rights, and commercialize through their own sales networks. Revenue is generated from (1) generic drug sales (ANDA) and CDMO manufacturing supply, (2) milestone payments and double-digit royalty participation on 505(b)(2) launches, (3) API trading and Rx-to-OTC product sales in the US, and (4) HH-001 product sales in China through HuaHan's direct distribution. 2024 reported consolidated revenue was NT$319.7M for January–August (up 146.94% YoY) following the HH-001 China launch; the company had 84–92 employees across 2023–2025 across its Taiwan, US, and China operations.

Name

Easywell Biomedicals Inc.

Legal name

EASYWELL BIOMEDICALS, INC.

Website

https://easywellbio.com

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

1–10 employees

Short description

Easywell Biomedicals (TPEX: 1799.TWO) is a Taiwan-based biopharmaceutical company that develops difficult-to-formulate generics and 505(b)(2) new drugs via US subsidiary Tulex, Magnifica Inc., and China-based HuaHan, leveraging proprietary drug delivery platforms and partner-funded co-development models.

Ownership category

akta.pro rank

Product category

Specialty Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Specialty generic pharmaceuticals
• Difficult generic drug development
• 505(b)(2) new drug applications
• Drug delivery platform technology
• Contract pharmaceutical manufacturing

Headquarters

HQ city

Hsinchu

HQ country

Taiwan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Generic Drug Sales (ANDA): Easywell's US subsidiary Tulex and subsidiary Magnifica develop and sell difficult generic drugs (P4 Paragraph IV ANDA) in the US market. Revenue is generated through product sales with market exclusivity from successful patent challenges. Products include TLX-001 (cough remedy), TLX-005 (overactive bladder), TLX-004 (antidepressant), TLX-007 (antidepressant), TLX-015 (postpartum hemorrhage), TLX-018 (hemostatic agent), and TLX-047 (anti-inflammatory).
2. 505(b)(2) New Drug Development and Licensing: Development of new dosage forms or routes of administration for existing molecules via the 505(b)(2) regulatory pathway. Revenue is generated through milestone payments during development and ongoing net sales royalty participation upon product launch. Products include TLX-041 (liquid oral for diabetes insipidus, approved 2026), ET-101 (liquid oral epilepsy drug), TLX-032, TLX-042 (epilepsy), TLX-050 (neurological), ARD-501 (autism), and TWB-201 (Parkinson's transdermal patch).
3. API Trading and Rx-to-OTC Sales: Magnifica Inc. conducts active pharmaceutical ingredient (API) trading and develops prescription-to-OTC (Rx-to-OTC) switch products targeting high-barrier, limited-competition niche markets. Products are distributed through retail partners such as Costco and Walmart.
4. CDMO (Contract Development and Manufacturing): Tulex Pharmaceuticals provides contract development and manufacturing services for 505(b)(2) products, earning manufacturing revenue and net sales royalties from products produced for partners such as Eton Pharmaceuticals.
5. China Market Product Sales (HH-001): Jiangsu HuaHan Pharma-Tech sells HH-001 Sacubitril/Valsartan Sodium tablets (Yuexin Tuo) in mainland China following receipt of marketing authorization from China's NMPA. The product launched in April 2024 and achieved NT$319.7 million in consolidated revenue for January–August 2024, representing 146.94% YoY growth.
6. Strategic Partnership Milestone and Royalty Income: Under co-development agreements with partners such as Eton Pharmaceuticals and Handa Neuroscience, Easywell/Tulex receives milestone payments during development and shares double-digit percentage points of net product sales profits, while partners bear development costs and obtain market/sales rights.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Easywell Biomedicals develops, manufactures, and commercializes difficult generic drugs (P4 Paragraph IV ANDA) and 505(b)(2) new drugs in new dosage forms or routes of administration through its US subsidiary Tulex Pharmaceuticals and China subsidiary Jiangsu HuaHan Pharma-Tech. The company leverages two proprietary drug delivery platform technologies (bioavailability enhancement micro milling and programmable gradient release film/matrix) to develop products targeting high-barrier, limited-competition markets, generating revenue through direct generic drug sales, milestone payments and royalties from co-development partners (Eton, Handa, Azurity, Artisan), CDMO services, and OTC/Rx-to-OTC products distributed via US retail chains and a China provincial sales network.

Product overview

Easywell Biomedicals Inc. is a biopharmaceutical company with three business sectors: Pharmaceuticals, Regenerative Medicine, and Medical Devices. The pharmaceutical portfolio consists of High-Barrier Generics (P4 ANDA products including TLX-001, TLX-004, TLX-005, TLX-007, TLX-015, TLX-018) and 505(b)(2) New Drug Applications (including ET-101, TLX-041, TLX-042, TLX-047, TLX-050, TLX-054, ARD-501). The company operates two proprietary platform technologies: Bioavailability Enhancement Sizing Technology (micro milling for particle size reduction) and Gradient Release Enabling Advanced Technology (programmable drug release profiles). Subsidiaries include Tulex Pharmaceuticals (New Jersey cGMP manufacturing), Magnifica Inc. (API trading and Rx-to-OTC drugs), and Jiangsu HuaHan Pharma-Tech (China). The regenerative medicine division develops TWB-103 fetal skin cell wound dressing and TWB-201 Parkinson's transdermal patch.

Differentiator

Problem solved

Functional benefit

Products and services

• TLX-001 Long-Acting Cough Medication FDA-approved Paragraph IV ANDA long-acting cough medication; Rx-to-OTC switch product for US retail markets (Costco, Walmart) with market size approximately USD 300 million (2016).
• TLX-004 Long-Acting Antidepressant FDA-approved Paragraph IV First-to-File long-acting antidepressant with additional 150mg dosage strength; market size approximately USD 741 million in 2019 US market.
• TLX-005 Overactive Bladder Medication FDA-approved generic drug for the treatment of overactive bladder.
• TLX-007 Antidepressant FDA-approved generic antidepressant with US market size approximately USD 69.5 million in 2019.
• TLX-015 Postpartum Hemorrhage Drug FDA-approved drug for prevention and treatment of postpartum hemorrhage; US market size approximately USD 27 million in 2019.
• TLX-018 Hemorrhage Treatment Drug FDA-approved hemorrhage treatment medication; US market size approximately USD 29 million in 2019.
• TLX-042 Oral Liquid Epilepsy Medication 505(b)(2) NDA-stage oral liquid medication for epilepsy treatment; US market size approximately USD 420 million (2025).
• TLX-041 Liquid Oral Diabetes Insipidus Drug FDA-approved 505(b)(2) liquid oral desmopressin medication for pediatric diabetes insipidus; only FDA-approved desmopressin oral liquid formulation with adjustable dosing capabilities.
• TLX-047 Anti-inflammatory Drug FDA-approved anti-inflammatory drug with total US sales approximately USD 39 million over the past four quarters.
• TLX-050 CNS Drug Central nervous system drug in co-development with Handa Neuroscience LLC and a third-party partner; Easywell/Tulex handle development and manufacturing, milestone and royalty income shared per contract.
• TLX-054 Injection Drug Injection medication in co-development with Taiwan Yok Chemical Co., Ltd. (台耀化學); expands Easywell's injection and long-acting injection product portfolio.
• ET-101 Liquid Oral Epilepsy Drug First FDA-approved 505(b)(2) liquid oral epilepsy and migraine prevention drug; annual sales exceeding USD 800 million; protected by US Patent 11,433,046 B2 through August 21, 2040.
• ARD-501 Autism Spectrum Disorder Treatment Phase 2a novel oral liquid extended-release formulation for autism spectrum disorder; co-developed with Artisan Therapeutics using Tulex's proprietary oral liquid extended-release formulation technology.
• TLX-032 New Drug Phase 2 clinical-stage new drug for an undisclosed indication, co-developed with an international pharmaceutical company; global market for therapeutic class USD 27.3 billion (2021).
• HH-001 Sacubitril/Valsartan Tablets (Yuexin Tuo / 悅欣妥) Generic version of Entresto (Sacubitril/Valsartan) for chronic heart failure (NYHA Class II-IV); reduces cardiovascular death and hospitalization risk; China market size approximately CNY 2.831 billion in 2022.
• TWB-103 Fetal Skin Cell Wound Dressing Regenerative medicine product using fetal skin cells for wound healing; in Phase 2 clinical trials in Taiwan and Japan for skin graft wounds and severe burn wounds.
• TWB-201 Parkinson's Transdermal Patch Transdermal patch for Parkinson's disease using a previously oral-approved molecule; completed human pilot pharmacokinetic clinical trial; first patch formulation for this molecule with global market USD 600 million in 2016.
• CDMO Services for 505(b)(2) Products Contract development and manufacturing services for 505(b)(2) products supplied to pharmaceutical partners; earns manufacturing revenue plus net sales royalties from products produced for partners.
• API Trading and Rx-to-OTC Switch Products Active pharmaceutical ingredient (API) trading and Rx-to-OTC switch product development for high-barrier, limited-competition niche markets; distributed via US retail partners including Costco and Walmart.

Quantifiable outcome

• 146.94% YoY revenue growth (NT$319.7M for Jan–Aug 2024 vs NT$129.5M in 2023) driven by HH-001 China market launch
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Eton Pharmaceuticals Inc.coreStrategic or Co-development Partner · 16 April 2026Tulex submitted an NDA for TLX-042 (505(b)(2) oral liquid medication for epilepsy) to the US FDA. Market size approximately USD 420 million in 2025 per IMS Health data.
• Artisan Therapeutics Inc.coreStrategic or Co-development Partner · 18 November 2025Tulex and Artisan Therapeutics (wholly owned subsidiary of Aardvark Therapeutics, NASDAQ: AARD) co-developed ARD-501, a novel oral liquid extended-release formulation for autism spectrum disorder. Phase 2a results showed positive clinical benefit in 4 out of 6 participants. Tulex contributes its proprietary oral liquid extended-release formulation technology.
• Taiwan Yok Chemical Co., Ltd. (台耀化學)coreStrategic or Co-development Partner · 1 October 2025Easywell signed a strategic cooperation agreement with Taiwan Yok Chemical for co-development of TLX-054 injection drug. The partnership leverages Taiwan Yok's API development and injection production line expertise alongside Easywell's international market network and Tulex's formulation R&D capabilities, to strengthen injection and long-acting injection product development and commercialization.
• Eton Pharmaceuticals Inc.coreStrategic or Co-development Partner · 1 May 2025Tulex and Eton co-developed TLX-041 (desmopressin oral liquid for pediatric diabetes insipidus), which received FDA approval in February 2026. Tulex is responsible for formulation development and manufacturing; Eton holds ex-Asia market rights and pays milestone payments plus royalty; Tulex retains Asian market rights.
• Handa Neuroscience LLCcoreStrategic or Co-development Partner · 17 December 2024Easywell and Tulex co-develop TLX-050 (neurological drug) with Handa Neuroscience LLC and a third-party company. Easywell/Tulex handle pre-clinical development and receive milestone income; upon FDA NDA approval, Tulex manufactures and the third-party company distributes in agreed territories. Milestones, costs, and profits are shared per contract terms.
• Eton Pharmaceuticals Inc.coreStrategic or Co-development Partner · 15 March 2023Tulex Pharmaceuticals signed an exclusive technology license and CDMO contract with Eton Pharmaceuticals for developing drugs treating pediatric rare diseases via the 505(b)(2) pathway. Tulex will be the exclusive manufacturer upon receiving approval, and receives milestone income plus net sales royalty. Eton filed the application in Q2 2024 with planned US market launch in 2025. Eton Pharmaceuticals is a NASDAQ-listed company (AARD) specializing in rare disease 505(b)(2) drug development.
• Azurity Pharmaceuticals Inc.coreStrategic or Co-development Partner · 1 October 2020Tulex co-developed ET-101 (505(b)(2) liquid oral epilepsy drug) with Azurity Pharmaceuticals. Tulex developed the formulation and manufactures; Azurity filed for approval and holds market sales rights. Tulex receives a double-digit percentage of net product sales. The product received FDA approval in November 2021 and is the first liquid oral epilepsy drug on the market.
• Confidential Top-5 Chinese Pharmaceutical CompanyminorStrategic or Co-development Partner · 20 August 2018Tulex partnered with a top-5 Chinese pharmaceutical company for a cardiovascular difficult generic drug. Tulex developed the formulation and licensed technology for manufacturing to the partner; the partner paid all development costs, pays royalties exceeding USD 1 million, and shares a percentage of product sales in the licensed territory. Contract runs from signing date until product manufacturing ceases.
• Confidential Multinational Pharma Company (Top 5 in China)minorStrategic or Co-development Partner · 1 August 2018Tulex partnered with a confidential multinational pharmaceutical company (revenue > USD 2 billion annually, product lines including anti-infective, cardiovascular, CNS drugs) for P4 difficult generic drug development. Tulex develops the formulation; the partner pays all development costs and holds US/territory sales rights. Tulex receives milestone payments exceeding USD 1 million plus double-digit sales royalties.
• Genovate Bio (健亞生物科技股份有限公司)coreStrategic or Co-development Partner · 1 August 2018Easywell announced a stock conversion merger with Genovate Bio. Easywell will issue 0.909 new shares per Genovate share. Upon completion, Genovate will become a 100%-owned subsidiary of Easywell. The merger aims to combine Easywell's US market capabilities with Genovate's local Taiwan R&D and manufacturing strengths, particularly for specialty generics (oral and injectable) and PMR branded drug development.
• Eton Pharmaceuticals Inc.coreStrategic or Co-development Partner · 1 February 2018Tulex Pharmaceuticals entered into a co-development agreement with US-based Eton Pharmaceuticals for two 505(b)(2) oral liquid dosage form drugs. Tulex is responsible for drug formulation development and manufacturing; Eton pays development costs, files for product approval, and obtains marketing rights. Tulex receives milestone payments and a double-digit percentage of net product sales. Tulex retains Asian market rights.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Upsher-Smith Laboratories: US specialty generics and branded pharmaceutical company with focus on extended-release, transdermal, and difficult-to-formulate products. Closely comparable product portfolio in difficult generics and modified-release technologies.
• Lannett Company: US specialty generics manufacturer with focus on difficult-to-formulate oral solids and liquids. Comparable product mix, customer base (wholesalers, distributors, retail pharmacy), and FDA-regulated manufacturing profile.
• Sciegen Pharmaceuticals: US-based specialty generic pharmaceutical company with focus on difficult-to-formulate generics and Paragraph IV challenges. Comparable generics-focused R&D and manufacturing business model targeting limited-competition markets.
• Noven Pharmaceuticals: Specialty pharma focused on transdermal drug delivery systems and modified-release technologies. Highly comparable in novel drug delivery and 505(b)(2)-style reformulation strategy; also overlaps with Tulex's TWB-201 Parkinson's transdermal patch.
• Tris Pharma: US specialty pharmaceutical company focused on modified-release, liquid, and 505(b)(2) formulations. Highly comparable technology platform — Tulex's CSO Yu-Hsing Tu previously worked at Tris Pharma and built overlapping capabilities in modified-release oral dosage forms.
• Azurity Pharmaceuticals: US specialty pharma focused on differentiated 505(b)(2) and reformulated drugs for underserved patient populations. Co-developed and commercializes ET-101 with Tulex — directly comparable 505(b)(2) specialty pharma business model.
• Eton Pharmaceuticals: NASDAQ-listed (AARD) specialty pharma developing 505(b)(2) drugs for pediatric rare diseases. Co-develops TLX-041, TLX-042 and other products with Tulex under milestone + royalty arrangements, with overlapping customer base (US pediatric/specialty prescribers) and identical regulatory pathway.

Broad incumbents

• Impax Laboratories (Amneal Pharmaceuticals): Larger US specialty and generics pharmaceutical company with broad portfolio including Paragraph IV generics, complex formulations, and 505(b)(2) products. Overlaps in difficult-generics R&D and CDMO capabilities but serves a wider therapeutic range at greater scale.
• Bausch Health ( generics/Bausch+Lomb specialty pharma): Large diversified pharmaceutical company with specialty generics, branded specialty pharma, and neurology franchises. Comparable in CNS specialty and difficult-generics manufacturing, but operates at substantially greater scale and scope than Easywell.

Emerging players

• Handa Neuroscience: Specialty CNS pharmaceutical company co-developing TLX-050 with Easywell/Tulex. Comparable in CNS therapeutic focus and 505(b)(2) reformulation strategy, but operates as a partner rather than direct competitor in the Easywell/Tulex pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/easywell-biomedicals

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Easywell Biomedicals Inc.